IB
The startup develops derived red blood cells by genetically engineering human stem cells, enabling on-demand blood supply for patients at risk. This technology addresses the critical shortage of available blood products for healthcare providers and patients in need.
Updated 18 months ago
Funding
$240K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JG
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops derived red blood cells by genetically engineering human stem cells, enabling on-demand blood supply for patients at risk. This technology addresses the critical shortage of available blood products for healthcare providers and patients in need.